ALISO VIEJO, Calif.--(BUSINESS WIRE)--Building on its foundational strength in partnering with health systems to close gaps in care for structural heart patients, today egnite, Inc. launched a new suite of predictive algorithms for its CardioCare program. These algorithms offer a major advancement in structural heart patient management. By applying AI to hospital data, they utilize trends in aortic stenosis (AS) patient populations to help doctors identify patients with severe, undiagnosed AS and track the progression of moderate disease.
“We are using vast amounts of data to solve big problems and close gaps in patient care,” said Joel Portice, chief executive officer, egnite. “We believe this is the first of many AI applications that will become a game changer for our physician partners and deliver meaningful improvements in patient care, with the potential to save thousands of lives. Now, more than ever we are acting with urgency to get these AI solutions into providers’ hands.”
CardioCare’s new algorithms:
- Leverage data from egnite’s proprietary database of more than 500,000 de-identified echocardiographic studies, including more than 11,000 studies with indications of significant disease.
- Predict the likelihood that a patient has been undiagnosed with severe AS, facilitating further review of significant clinical data points.
- Predict the likelihood that a moderate AS patient will progress to severe disease, enabling clinicians to prioritize their patient population for clinical follow-up.
There are an estimated 121.5 million adults affected by cardiovascular (CV) disease—the leading cause of death for Americans—with structural heart disease being a significant contributor to cardiovascular-related deaths.
Findings from egnite’s database show that approximately one in four patients who undergo echocardiograms are diagnosed with moderate or severe structural heart disease. Although timely follow-up and treatment are needed for optimal outcomes, health systems experience significant challenges ensuring patients receive the appropriate follow-up. In fact, CardioCare’s data have shown that as few as 11% of patients receive repeat echocardiograms at the recommended interval. With more patients having delayed medical care due to the pandemic, hospital systems need a better way to identify their most at-risk patients who have not returned to the health system.
“Our health care system is fragmented, which can result in either undertreatment or lack of timely treatment of structural heart disease. All of us who have cared for these patients have seen tragic examples of poor outcomes due to delays in intervention. These delays are not the fault of the care providers but to care pathways that do not assure timely management,” said Glenn R. Barnhart, M.D., chief medical officer, egnite. “Hospitals need a comprehensive way to manage their large structural heart populations to ensure the proper care at the proper time. CardioCare’s new predictive suite allows physicians to identify at-risk patients and has the potential to become the new standard for how we take care of structural heart patients.”
egnite is a digital healthcare company dedicated to improving structural heart patient care by delivering actionable insights through intuitive digital health platforms, proprietary AI-powered analytics, and deep clinical expertise. egnite’s charter is to spark transformation in fragmented healthcare systems by delivering integrated solutions that help elevate the standard of care for patients with structural heart disease. The company is based in Aliso Viejo, Calif. For more information, visit www.egnitehealth.com or follow the company on Twitter at @egnitehealth and LinkedIn at https://www.linkedin.com/company/egnite-health/.
egnite, egnite, Inc., the stylized logo, and CardioCare are trademarks of egnite, Inc. All other trademarks are the property of their respective owners.